Evidence map›Paper›PMID 29548320›Full record

ArticleBMC biotechnology2018

Total RNA extraction from tissues for microRNA and target gene expression analysis: not all kits are created equal.

Rikki A M Brown, Michael R Epis, Jessica L Horsham, Tasnuva D Kabir, Kirsty L Richardson, Peter J Leedman

Abstract readComparative Study
In one paragraph

Article in BMC biotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Urinary miRNA Biomarkers of Drug-Induced Kidney Injury and Their Site Specificity Within the Nephron.Toxicological sciences : an official journal of the Society of Toxicology · 2021
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Nutrients · 2025
    Article
  12. Review
  13. MicroRNAs in idiopathic childhood nephrotic syndrome.Clinical and experimental nephrology · 2025
    Article
  14. Article
  15. Guidelines for mitochondrial RNA analysis.Molecular therapy. Nucleic acids · 2024
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rikki A M BrownLaboratory for Cancer Medicine, Harry Perkins Institute of Medical Research, University of Western Australia, Centre for Medical Research, QEII Medical Centre, 6 Verdun St, Nedlands, WA, 6009, Australia.
Michael R EpisLaboratory for Cancer Medicine, Harry Perkins Institute of Medical Research, University of Western Australia, Centre for Medical Research, QEII Medical Centre, 6 Verdun St, Nedlands, WA, 6009, Australia.
Jessica L HorshamSchool of Medicine and Pharmacology, the University of Western Australia, Nedlands, WA, 6009, Australia. jessica.horsham@perkins.uwa.edu.au.
Tasnuva D KabirLaboratory for Cancer Medicine, Harry Perkins Institute of Medical Research, University of Western Australia, Centre for Medical Research, QEII Medical Centre, 6 Verdun St, Nedlands, WA, 6009, Australia.
Kirsty L RichardsonLaboratory for Cancer Medicine, Harry Perkins Institute of Medical Research, University of Western Australia, Centre for Medical Research, QEII Medical Centre, 6 Verdun St, Nedlands, WA, 6009, Australia.
Peter J LeedmanLaboratory for Cancer Medicine, Harry Perkins Institute of Medical Research, University of Western Australia, Centre for Medical Research, QEII Medical Centre, 6 Verdun St, Nedlands, WA, 6009, Australia. peter.leedman@perkins.uwa.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundmicroRNAs (miRNAs) are short non-coding RNAs that fine-tune gene expression. The aberrant expression of miRNAs is associated with many diseases and they have both therapeutic and biomarker potential. However, our understanding of their usefulness is dependent on the tools we have to study them. Previous studies have identified the need to optimise and standardise RNA extraction methods in order to avoid biased results. Herein, we extracted RNA from murine lung, liver and brain tissues using five commercially available total RNA extraction methods. These included either: phenol: chloroform extraction followed by alcohol precipitation (TRIzol), phenol:chloroform followed by solid-phase extraction (column-based; miRVana and miRNeasy) and solid-phase separation with/without affinity resin (Norgen total and Isolate II). We then evaluated each extraction method for the quality and quantity of RNA recovered, and the expression of miRNAs and target genes.

resultsWe identified differences between each of the RNA extraction methods in the quantity and quality of RNA samples, and in the analysis of miRNA and target gene expression. For the purposes of consistency in quantity, quality and high recovery of miRNAs from tissues, we identified that Phenol:chloroform phase separation combined with silica column-based solid extraction method was preferable (miRVana microRNA isolation). We also identified a method that is not appropriate for miRNA analysis from tissue samples (Bioline Isolate II). For target gene expression any of the kits could be used to analyse mRNA, but if interested in analysing mRNA and miRNA from the same RNA samples some methods should be avoided.

conclusionsDifferent methods used to isolate miRNAs will yield different results and therefore a robust RNA isolation method is required for reproducibility. Researchers should optimise these methods for their specific application and keep in mind that "total RNA" extraction methods do not isolate all types of RNA equally.

Indexed as

AnimalsAxl Receptor Tyrosine KinaseBiochemistryBrain ChemistryChloroformErbB ReceptorsGene Expression ProfilingLiverLungMaleMice, Inbred C57BLMicroRNAsPhenolProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesRNAAxl Receptor Tyrosine KinaseAXL receptor tyrosine kinase, mouseChloroformEGFR protein, mouseErbB ReceptorsMicroRNAsMIRN34a microRNA, mouseMIRN7 microRNA, mousePhenolProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesRNABiomarkersExtractionmicroRNA isolation methodmicroRNAsmiRNA-based therapyReal-time PCRTissue

Identifiers

PMID29548320
PMCPMC5857145

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.